Vagus Nerve Stimulation in Failed Epilepsy Surgery: 36 Month Outcomes From the CORE-VNS Study

Based on 36-month data from the CORE-VNS study, vagus nerve stimulation demonstrates comparable seizure reduction and safety profiles in patients with drug-resistant epilepsy regardless of whether they have a history of prior intracranial epilepsy surgery, indicating that such a history should not preclude VNS treatment.

The Gist

The "Backup Generator" for a Brain That's Still Stuttering

Imagine your brain is a high-tech city. In a healthy city, the traffic lights (neurons) work perfectly, and cars (electrical signals) flow smoothly. But for people with drug-resistant epilepsy, the traffic lights are glitching, causing massive, dangerous gridlock called seizures.

Usually, when the gridlock gets bad, doctors try two main things:

1. Medication: They try to calm the traffic with special "traffic controllers" (drugs).
2. Brain Surgery: If the drugs don't work, they might perform a "road closure" (intracranial surgery) to remove the specific intersection where the chaos starts.

The Problem: Sometimes, even after the "road closure" surgery, the traffic doesn't stop. The city is still stuttering. For a long time, doctors were hesitant to try a third option called Vagus Nerve Stimulation (VNS) on these patients. Why? Because the official rulebook said, "We haven't tested this on people who already had brain surgery, so we don't know if it's safe or if it will work."

The Big Question: Does having had brain surgery first make the VNS "backup generator" useless? Or does it work just as well?

The Study: A Real-World Test Drive

To answer this, researchers looked at a massive group of 531 patients from the CORE-VNS study. Think of this as a 3-year long road test across the whole world.

They split the drivers into two groups:

• Group A: People who had never had brain surgery.
• Group B: People who had brain surgery before, but the seizures kept coming back (the "failed surgery" group).

They installed the VNS device (a small pacemaker for the brain's electrical system) and watched what happened over 36 months.

The Results: The Backup Generator Works for Everyone

The findings were surprisingly simple and very good news: It didn't matter which group you were in.

• The Traffic Calmed Down: Both groups saw their seizures drop dramatically.

  • People without prior surgery saw their seizures drop by about 76%.
  • People with prior surgery saw their seizures drop by about 76% as well.
  • Analogy: It's like saying a new noise-canceling headphone works just as well for someone who has never worn headphones as it does for someone who has already tried to fix their ears with surgery.

• The "Freedom" Rate: About 18% of people without prior surgery stopped having seizures entirely. About 9% of the "failed surgery" group stopped completely. While the "failed surgery" group had a slightly lower chance of total silence, they still got massive relief.

• Safety: The device didn't cause more problems for the people who had brain surgery. The side effects (like a scratchy throat or cough) were the same for everyone.

Why Does This Make Sense? (The "Long Wire" Theory)

The authors explain this with a clever biological analogy.

Think of the brain as a house with a complex electrical system.

• Brain Surgery tries to fix the problem by rewiring the specific room where the short circuit happens.
• VNS is different. It doesn't touch the house's wiring directly. Instead, it plugs into a long cable (the vagus nerve) that runs from your neck all the way down to your stomach.

When you stimulate this cable, it sends a signal up to the brainstem (the basement of the house), which then sends a "calm down" message to the whole house using a broadcast system (chemicals like norepinephrine and serotonin).

The Key Insight: Because VNS talks to the brain from the outside (via the neck cable) and uses the basement to broadcast the message, it doesn't matter if the attic (the part of the brain that was surgically removed) has been modified. The signal still gets through the front door and calms the whole house down.

The Bottom Line

For a long time, the medical rulebook said, "If you've had brain surgery and it didn't work, don't try VNS yet."

This study says: That rule can be retired.

If brain surgery didn't stop the seizures, adding VNS is a safe and effective next step. It's like realizing that even if you've tried to fix a leaky roof yourself, calling in a professional backup generator is still a great idea to keep the house dry. The "failed surgery" patients got just as much relief as everyone else.

Technical Summary

1. Problem Statement

Drug-resistant epilepsy (DRE) affects a significant subset of patients who fail to achieve seizure freedom through antiseizure medications (ASMs) and, in many cases, intracranial surgery for epilepsy (ICSE). While Vagus Nerve Stimulation (VNS) is an established neuromodulation therapy for DRE, its efficacy and safety profile in patients who have previously undergone ICSE remain unclear.

• Clinical Gap: Current regulatory labels for VNS Therapy state that safety and efficacy are "Not Established" in patients with a history of prior brain surgery.
• Theoretical Concerns: Historically, there was uncertainty regarding whether prior brain surgery might alter the mechanism of VNS (which relies on brainstem projections) or increase procedural risks.
• Objective: This study aimed to determine if a history of ICSE influences the safety and effectiveness of adjunctive VNS therapy using real-world data.

2. Methodology

The study utilized data from CORE-VNS (NCT03529045), a prospective, multicenter, international, open-label observational study.

• Study Design: Post-hoc subset analysis comparing two groups of patients with DRE receiving VNS:
  1. Prior ICSE Group: Patients with a history of intracranial epilepsy surgery ($n=84$).
  2. No Prior ICSE Group: Patients without a history of intracranial epilepsy surgery ($n=447$).
• Data Collection:
  • Timepoints: Baseline, and follow-ups at 3, 6, 12, 24, and 36 months post-implantation.
  • Metrics: Seizure frequency (categorized by type: all, focal, generalized), responder rates (50%, 80%, 100% reduction), seizure freedom, and adverse events (AEs).
  • Safety: Collection of implant/procedure-related AEs and stimulation/device-related AEs, including Serious Adverse Events (SAEs).
• Statistical Analysis:
  • Descriptive statistics (mean/SD or median/IQR).
  • Seizure Reduction: Compared using the Wilcoxon rank-sum test.
  • Safety: Incidence Rate Ratios (IRRs) calculated using Poisson approximation to compare event rates between groups, adjusted for exposure time.

3. Key Contributions

• Real-World Evidence: This is one of the largest analyses (531 total participants) specifically addressing the "safety and efficacy not established" label for VNS in post-surgical epilepsy patients.
• Longitudinal Data: Provides 36-month outcomes, offering a robust view of long-term efficacy and safety compared to shorter-term clinical trials.
• Mechanistic Validation: Supports the hypothesis that VNS mechanisms (brainstem activation via the NTS, LC, and RN) are independent of prior cortical resection or disconnection procedures.

4. Key Results

Demographics and Baseline

• Total Cohort: 531 participants (84 with prior ICSE, 447 without).
• Baseline Severity: The prior ICSE group exhibited higher baseline seizure severity (median 24 seizures/month) compared to the no-ICSE group (median 15 seizures/month), suggesting a more refractory population.
• Surgery Types: In the ICSE group, lesionectomy (36.9%), lobar resection (22.6%), and callosotomy (19.0%) were the most common prior procedures.

Efficacy Outcomes (36 Months)

• Seizure Reduction: Median percentage reductions were statistically similar between groups across all seizure types.
  • All Seizures: 76.6% reduction (No ICSE) vs. 76.3% reduction (Prior ICSE).
  • Focal Seizures: 83.3% (No ICSE) vs. 71.8% (Prior ICSE).
  • Generalized Seizures: 77.8% (No ICSE) vs. 76.2% (Prior ICSE).
  • Statistical Significance: No significant difference in median reductions ($p=0.3485$).
• Responder Rates (>50% reduction):
  • No ICSE: 64.8%
  • Prior ICSE: 61.8%
• Seizure Freedom (100% reduction):
  • No ICSE: 17.9% (complete freedom from all seizures).
  • Prior ICSE: 8.8% (complete freedom from all seizures).
  • Note: While the rate of complete freedom was lower in the prior ICSE group, the authors attribute this to the higher baseline severity and likely multifocal nature of epilepsy in this subgroup rather than VNS inefficacy.

Safety Outcomes

• Adverse Events (AEs): Overall incidence was comparable (36.9% vs. 41.2%; IRR = 0.91).
• Implant/Procedure AEs: Slightly lower in the prior ICSE group (9.5% vs. 13.6%), though not statistically significant (IRR = 0.65).
• Stimulation/Device AEs: Nearly identical rates (32.1% vs. 32.0%).
• Serious Adverse Events (SAEs): Lower in the prior ICSE group (3.6% vs. 7.2%), with no stimulation-related SAEs occurring in the prior ICSE group.

5. Significance and Conclusion

• Clinical Implication: The study concludes that a history of prior intracranial epilepsy surgery should not be a contraindication for VNS therapy. Patients who fail ICSE can expect clinically meaningful seizure reductions comparable to those who have not undergone surgery.
• Safety Profile: The safety profile of VNS remains consistent regardless of prior brain surgery, with no increase in implant-related or stimulation-related risks.
• Limitations: As an observational, non-randomized study, causal inferences are limited. The prior ICSE group represented a more refractory population with higher baseline seizure frequency and heterogeneous surgical histories.
• Final Verdict: VNS is a viable and effective therapeutic option for patients with drug-resistant epilepsy who have not achieved seizure freedom following intracranial surgery, supporting its use as a subsequent treatment modality.